Compare · AVTR vs PKI
AVTR vs PKI
Side-by-side comparison of Avantor Inc. (AVTR) and PerkinElmer Inc. (PKI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and PKI operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- PKI is the larger of the two at $21.38B, about 4.0x AVTR ($5.31B).
- AVTR has hit the wire 8 times in the past 4 weeks while PKI has been quiet.
- AVTR has more recent analyst coverage (25 ratings vs 17 for PKI).
- Company
- Avantor Inc.
- PerkinElmer Inc.
- Price
- $8.09+3.06%
- $115.23-0.88%
- Market cap
- $5.31B
- $21.38B
- 1M return
- +3.12%
- -
- 1Y return
- -37.72%
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2019
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 17
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
PerkinElmer Inc.
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Latest AVTR
- SEC Form 10-Q filed by Avantor Inc.
- Avantor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Avantor® Reports First Quarter 2026 Results
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Avantor® Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer
- Avantor® Unifies Masterflex® Portfolio to Streamline Fluid Management from R&D to Bioprocess Manufacturing
- Avantor® Enhances U.S. Biomanufacturing Infrastructure with Expanded Stability and Microbial Testing Facility
- SEC Form 4 filed by Eck Steven W
- Avantor® to Report First Quarter 2026 Earnings on Wednesday, April 29, 2026
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest PKI
- Gonzales Anita covered exercise/tax liability with 119 shares, decreasing direct ownership by 3% to 3,591 units (SEC Form 4)
- Krakowiak Maxwell covered exercise/tax liability with 85 shares, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)
- Klobuchar Michael A was granted 481 shares (SEC Form 4)
- Vandebroek Sophie V. was granted 481 shares (SEC Form 4)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)
- Singh Prahlad R. exercised 57,039 shares at a strike of $76.83, sold $2,212,480 worth of shares (21,217 units at $104.28) and covered exercise/tax liability with 15,424 shares, increasing direct ownership by 25% to 103,414 units (SEC Form 4)
- Victor Miriame exercised 2,408 shares at a strike of $105.62 and covered exercise/tax liability with 1,030 shares, increasing direct ownership by 15% to 10,470 units (SEC Form 4)